title: Changes in positive and negative syndrome scale-derived hostility factor in adolescents with schizophrenia treated with aripiprazole: post hoc analysis of randomized clinical trial data.
abstract: BACKGROUND
  This post hoc analysis evaluated the effects of aripiprazole on Positive and Negative Syndrome Scale (PANSS) Hostility factor scores in adolescents with schizophrenia.
  
  
  METHODS
  In total, 302 adolescents (13-17 years) with schizophrenia were enrolled in a 6-week, multicenter, double-blind, randomized, placebo-controlled trial comparing aripiprazole (10 or 30 mg/day) with placebo. The PANSS was the primary outcome measure. To determine the effect of aripiprazole on hostility, a post hoc analysis of the PANSS Hostility factor and individual items was performed.
  
  
  RESULTS
  Aripiprazole was superior to placebo in reducing PANSS Hostility factor scores in adolescents with schizophrenia. After 6 weeks, aripiprazole 10 mg/day and aripiprazole 30 mg/day showed a statistically significant improvement versus placebo (-3.0, -3.7, versus -2.1; p < 0.05; last observation carried forward [LOCF]) in the PANSS Hostility factor. For aripiprazole 30 mg/day, statistically significant separation from placebo was evident from week 3 through week 6 and at week 6 for aripiprazole 10 mg/day. Individual PANSS Hostility, Uncooperativeness, and Poor Impulse Control Items showed statistically significant improvement with aripiprazole 30 mg/day over placebo at end point.
  
  
  CONCLUSIONS
  This post hoc analysis shows that aripiprazole (10 and 30 mg/day) is an effective treatment for hostility symptoms in adolescents with schizophrenia. Clinical trials information: ClinicalTrials.gov identifier: NCT00102063.
authors.affiliation: Children's National Medical Center, Washington, DC 20010-2970, USA.
authors.forename: Adelaide S
authors.initials: AS
authors.lastname: Robb
authors.forename: William H
authors.initials: WH
authors.lastname: Carson
authors.forename: Margaretta
authors.initials: M
authors.lastname: Nyilas
authors.forename: Mirza
authors.initials: M
authors.lastname: Ali
authors.forename: Robert A
authors.initials: RA
authors.lastname: Forbes
authors.forename: Taro
authors.initials: T
authors.lastname: Iwamoto
authors.forename: Sheila
authors.initials: S
authors.lastname: Assunção-Talbott
authors.forename: Richard
authors.initials: R
authors.lastname: Whitehead
authors.forename: Andrei
authors.initials: A
authors.lastname: Pikalov
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000704:Analysis of Variance; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000068180:Aripiprazole; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D006791:Hostility; D006801:Humans; D008297:Male; D010879:Piperazines / Q000008:administration & dosage / Q000627:therapeutic use*; D011569:Psychiatric Status Rating Scales; D011595:Psychomotor Agitation / Q000188:drug therapy* / Q000523:psychology; D015363:Quinolones / Q000008:administration & dosage / Q000627:therapeutic use*; D012559:Schizophrenia / Q000175:diagnosis / Q000188:drug therapy*; D012565:Schizophrenic Psychology; D013577:Syndrome; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D014150:Antipsychotic Agents; D010879:Piperazines; D015363:Quinolones; D000068180:Aripiprazole